Skip to main content
. Author manuscript; available in PMC: 2021 Jun 8.
Published in final edited form as: Nat Cancer. 2020 Apr 20;1(4):410–422. doi: 10.1038/s43018-020-0054-2

Extended Data Fig. 2 |. Genome-wide CRISPR screen identifies Staufen2 as a regulator of myeloid leukemia.

Extended Data Fig. 2 |

a, Relative expression of the indicated genes in human leukemia stem cells as compared to more differentiated cancer populations from Gene Expression Commons. b, Relative expression of STAU1 in human leukemia stem cells as compared to more differentiated cancer populations from the Riken database. c, STAU1 expression in human HSCs and human leukemia stem cells (mean±S.E.M.; n = 4 independent HSC and n = 9 independent LSC samples; two-tailed Student’s t-test). d, Relative RNA expression of the indicated genes in NIH-3T3 cells expressing shRNAs against RNA-binding proteins relative to control shLacZ (n = 3 technical replicates per group). e, Number of colonies formed by Cas9+ bcCML lin- cells transduced with the CRISPR guides against the indicated genes relative to a control non-targeting gRNA (mean±S.D.; n = 3 independent culture wells per group; two-tailed Student’s t-test). f, Relative expression of Stau2 transcript in the indicated populations isolated from the normal bone marrow of wild-type mice and sorted Lin+ and Lin− and leukemia stem cell (LSC) populations from established wild-type bcCML (n = 3 technical replicates for KLS, Lin+, Leukemic Lin+, Lin−, LSC, and n = 2 technical replicates for HSC and Lin−). g-h, Relative Stau2 expression in KLS cells transduced with BCR-ABL (g) or BCR-ABL and NUP98−HOXA9 (h) 72–96 h post-infection (n = 3 technical replicates per group). i, Impact of indicated doses of Gleevec for 48 h on Stau2 expression in established Lin− bcCML cells (n = 3 technical replicates per group).